Astrazeneca Ab

Astra Zeneca U.k. Limited

Astra Pharmaceuticals Limited

Matthew Wd Perry

Martin E Cooper

David R Cheshire

Brian Springthorpe

Mark Furber

David K Donald

Philip Vellacott Thorne

John R Bantick

Andrew Cooke

Richard Evans

Nicholas P Tomkinsson

Richard P Harrison

Thomas McInally

Christopher Luckhurst

Christian Tyrchan

Mickael Mogemark

Jens Petersen

Konstantinos Karabelas

Stephen Thom

Hitesh Jayantilal Sanganee

Stephen Brough

Andrew Baxter

Pavol Zlatoidsky

Antonios Nikitidis

Simon Hirst

Moya Caffrey

Tobias Mochel

David O'Sullivan

Rhona Cox

Talbir Austin

Peter Bold

Ulf Borjesson

Nicholas Kindor

David Harden

Nils Pemberton

David Marriott

Disclosed herein is the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one of the following structure: and/or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof, which inhibit phosphatidylinositol 3-kinase (PI3K) activity.

(S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor

There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K&#x3b4;) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Inhibitors of phosphatidylinositol 3-kinase gamma

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.

Piperidine derivatives

The present invention provides a compound of formula (I), wherein: Z is (A) OR (B) and wherein the remaining variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of achemokine (such as CCR3) or H1 mediated disease state. 

Piperidine derivatives useful as modulators of chemokine receptor activity

The present invention relates to compounds of formula (I): The variables recited in formula (I) are defined in the specification. The present invention also relates to processes of preparing compounds of formula (I) and uses of such compounds for treating a chemokine (e.g., CCR3) or H1 mediated disease state.

Chemical compounds

The invention provides a compound of formula (I), wherein: T is C(O) or S(O); W is C(O) or S(O); X is CH, O or NH; Y is CRor N; Ris optionally substituted aryl or optionally substituted heterocyclyl; Ris hydrogen or Calkyl; Ris hydrogen or optionally substituted Calkyl; and Ris alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis 

The invention provides compounds of formula (I) wherein: T is C(O) or S(O); W is C(O) or S(O); X is CH, O or NH; Y is CRor N; n is 0, 1 or 2; m is 1 or, when Y is CRm is 0; Ris optionally substituted aryl or optionally substituted heterocyclyl; R, R, R,, R, R, Rand Rare, independently, hydrogen or C?1-6#191 alkyl; Ris hydrogen or C-Calkyl; Ris alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; and Ris hydrogen or C-Callkyl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis.

The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.

Treatment of skin disorders using thieno[2,3-D]pyrimidinediones

The invention provides a compound of formula (I): wherein R, R, R, R, R, N, X and Y are as defined in the specification, processes, for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.

The invention provides compounds of formula (I) wherein R, R, R, R, Z, Q, m, n, X, X, X, Xand T are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions

Substituted piperidine compounds useful as modulators of chemokine receptor activity

The invention provides certain pyrrolo-, thieno-, furano-and pyrazolo-&lsqb;3,4-d&rsqb;-pyridazinones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.

Substituted fused pyridazinone compounds; composition and use thereof

The invention provides pharmaceutically useful thieno&lsqb;2,3-d&rsqb;pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.

Thieno&lsqb;2,3-d&rsqb; pyrimidinediones, their preparation and use in therapy

The invention provides certain pyrrolo-, thieno-, furano- and pyrazolo-&lsqb;3,4-d&rsqb;pyridazinones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.

Growing community of inventors

Leics, United Kingdom

Matthew Wd Perry